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Abstract
G protein coupled receptor (GPCR) signalling covers three major mechanisms. GPCR ago-
nist engagement allows for the G proteins to bind to the receptor leading to a classical down-
stream signalling cascade. The second mechanism is via the utilization of the β-arrestin
signalling molecule and thirdly via transactivation dependent signalling. GPCRs can transacti-
vate protein tyrosine kinase receptors (PTKR) to activate respective downstream signalling
intermediates. In the past decade GPCR transactivation dependent signalling was expanded
to show transactivation of serine/threonine kinase receptors (S/TKR). Kinase receptor trans-
activation enormously broadens the GPCR signalling paradigm. This work utilizes next gener-
ation RNA-sequencing to study the contribution of transactivation dependent signalling to total
protease activated receptor (PAR)-1 signalling. Transactivation, assessed as gene expres-
sion, accounted for 50 percent of the total genes regulated by thrombin acting through PAR-1
in human coronary artery smooth muscle cells. GPCR transactivation of PTKRs is approxi-
mately equally important as the transactivation of the S/TKR with 209 and 177 genes regu-
lated respectively, via either signalling pathway. This work shows that genome wide studies
can provide powerful insights into GPCR mediated signalling pathways.
Introduction
G protein coupled receptors (GPCRs) are the most prolific and polyfunctional receptors in
biology [1, 2]. GPCRs control diverse physiological functions which include, relaxation of
blood vessels, acceleration of heart rate, transmission of sight impulses, biorhythms and
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olfaction [3]. Drugs targeting GPCRs are the largest class of therapeutic agents for diseases
including but not limited to: cardiovascular disease, cancer, hypertension and asthma [4–8].
The current paradigm of GPCR signalling covers three major pathways: firstly the well-defined
classic signalling pathway which agonist engagement causes G protein binding to the receptor
with subsequent downstream signalling leading to functional responses [9–11]. Secondly, the
β-arrestin scaffold pathway which leads to the activation of multiple downstream signalling
cascades [12]. Two decades ago, the GPCR signalling pathways were complemented by the
finding that GPCRs could activate protein tyrosine kinase receptors (PTKRs) leading to the
activation of the downstream signalling pathways [13]. This pathway termed transactivation, is
the third major signalling pathway of GPCR which was recently expanded to include GPCR
mediated transactivation of serine/threonine kinase receptors (S/TKR) [14–18].
The activation of PTKRs by a GPCR immensely expands the range of cellular functions
attributable to GPCRs [13, 19, 20]. An example from the vascular biology field is the acute acti-
vation of an Angiotensin II receptor in a transactivation independent response leads to a very
rapid mobilization of intracellular calcium ions and vascular contraction [21] whereas transacti-
vation of PTKRs leads to a slow vascular remodelling due to cell proliferation and extracellular
matrix synthesis [22]. Angiotensin II transactivation goes beyond the vasculature, this signalling
pathway has also been shown to be important in kidney [23], heart [24, 25] and cancer [26].
The paradigm of GPCR transactivation signalling has expanded to include the transactivation
of the S/TKR and notably the transforming growth factor (TGF)-β receptor (TGFBR1). The
phenomenon of transactivation dependent signalling of the PTKR family includes receptors for
epidermal growth factor (EGF), platelet derived growth factor, insulin-like growth factor-1 and
fibroblast growth factor [13, 27–29]. However GPCR dependent transactivation of the S/TKR is
currently restricted to the TGF-β receptor superfamily [15–18, 30–32].
In human vascular smooth muscle cells (VSMCs) the mechanisms involved in PAR-1 medi-
ated transactivation of the PTKR, EGFR, and the S/TKR, TGFBR1, have been partially defined.
PAR-1 transactivation of the EGFR involves the activation of cell surface matrix metalloprotei-
nases that cleave and release membrane anchored EGFR ligands. PAR-1 transactivation of the
TGFBR1 is mediated by cytoskeletal rearrangement which activates ROCK signalling, leading
to the activation of cell surface integrins, which bind to the latent TGF-β complex. This allows
for the TGF-β ligand to bind to its receptor. These two transactivation dependent pathways are
fully functional in the context that they lead to glycosaminoglycan (GAG) enzyme expression
[33] and GAG chain elongation [15]. Beyond this model of proteoglycan synthesis in VSMCs
the important transactivation signalling to GPCR signalling is unknown.
To recognize the extent of transactivation dependent signalling a genome-wide study can
help identify some promising candidates of PAR-1 transactivation of the TGFBR1 or EGFR.
Whole genome RNA sequencing allows for the comprehensive study of the mRNAs in the
sample. This new platform has produced high throughput sequencing in the study of various
diseases [34–38]. Hannan [39] adapted a similar approach to identify the underlying biology
in transactivation of the EGFR. Using a functional siRNA screen of the human genome, the
role of 720 kinases was investigated in Angiotensin II mediated transactivation of the EGFR
[39]. However in the present study, RNA sequencing analysis was employed to provide an
approach to examine the changes induced by PAR-1 transactivation dependent signalling in
global gene expression in human coronary artery smooth muscle cells (CASMCs).
Materials and methods
RNAse-Free DNase set and miRNeasy kit were purchased from Qiagen. Dynabeads1 mRNA
DIRECT™ Micro kit, Ion PI™ Template OT2 Supplies 200 kit v2, Ion PI™ Template OT2
GPCR transactivation signalling
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Reagents 200 Kit v2, Ion PI™ Template OT2 Solutions 200 kit v2, Ion PI™ Sequencing Supplies
200, Ion PI™ Sequencing reagents 200, Ion PI™ Sequencing solutions 200 v2, Ion PI™ Chip
preparation solution and Ion Proton™ Chip Adapter where purchased from Life Technologies.
Cell culture
Human CASMCS (purchased from Lonza Cat No. CC-2583, Lot No. 0000317155) were grown
in DMEM (5mM glucose, 10% FBS and 1% antibiotics at 37˚C in 5% CO2) and were seeded in
60 mm dishes. Cells were grown to confluence then rendered quiescent by serum deprivation
for 48 hours. Inhibitors to TGFBR1 (SB431542 10μM) and EGFR (AG1478 5μM) were pre-
incubated for 30 mins prior to treatment with thrombin (10 units/ml) for 6 hours. RNA extrac-
tion and library preparation followed the manufacturer’s instructions.
Quality control and read alignment
QuadTrim was used for quality trimming of RNA-sequencing reads. Raw reads with Q-score
greater than 20 (>Q20) were retained for further analysis. High quality filtered reads were
aligned to the human reference genome (hg19) using Bowtie v2.2.4 and TopHat v2.1.1 [40,
41]. Uniquely mapped reads were then used for counting reads using HTSeq [42].
Differential gene expression and functional analysis
The genes differentially expressed between the different treatments were identified using
edgeR v3.0.7 [43], a Bioconductor package of R statistical environment [44]. This method uses
a Poisson distribution to model genic read counts following normalization based on size fac-
tors and variance, therefore this software allows normalization of RNA-sequence data based
on sequencing depth GC content and gene length for analysis of differentially expressed genes.
Differentially expressed genes were defined with log2FC of>0.7 or <-0.7 significant at p value
<0.01 (FDR 0.05). STRING (v10.0) (http://string-db.org), a publically available online data-
base of functional interaction [45] was used to identify gene ontology analysis and networks,
the differentially expressed genes were analysed. The Venn diagrams were depicted using
JVENN an interactive tool to view Venn diagrams and respective lists [46].
Western blotting
Total cell lysates were resolved on 10% SDS-PAGE and transferred onto PVDF. Membranes
were blocked with 5% bovine serum albumin, incubated with ANKRD1 polyclonal antibody
(ab88456) and followed by HRP anti-rabbit IgG and ECL detection.
Assessing mRNA gene expression
The mRNA level of ANKRD1 was determined by real-time polymerase chain reaction
(RT-PCR). Total RNA was isolated from treated CASMCs using RNeasy Mini kit (Qiagen)
according to the manufactures’ instructions. First strand cDNA was synthesized from 1μg
RNA using Quantitect reverse transcriptase kit (Qiagen). Quantitative RT-PCR was performed
using Qiagen Rotor Gene Q and QuantiNova SYBR Green PCR Master Mix kit (Qiagen).
RT-PCR used human specific ANKRD1 primer sequences. The data was normalized to 8S as
the house keeping gene. Relative expression of mRNA levels was quantified using comparative
delta delta Ct method.
GPCR transactivation signalling
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Results and discussion
Gene expression profiles of the treatments
A genome wide RNA-Seq sequencing study was conducted to determine the portion of GPCR
signalling which is occurring via transactivation dependent signalling in human CASMCs (Fig 1).
The individual treatment groups (Basal, Thrombin, Thrombin+AG1478, Thrombin+SB431542
or Thrombin+AG1478+SB431542) contained 2–4 individual samples pooled together for each of
the groups to identify the differentially expressed genes. A total of 3 pooled samples from RNA
isolated from untreated CASMCs (Fig 1A), averaged 8 million reads and 82.7% of the total reads
were mapped to the human reference genome (hg19). The RNA was harvested from human
CASMCs treated with thrombin for 6 hours (Fig 1B), consisted of 4 pooled samples with an aver-
age of 12 million reads. This relatively short stimulation period was chosen to focus on primary
signalling from GPCR to gene expression, to the exclusion of later responses which may be sec-
ondary and beyond responses to the expression of intermediate genes. Among the total number
of reads 83.3% of the reads were mapped to the human reference genome (hg19). The differen-
tially expressed genes regulated via PAR-1 mediated transactivation of the EGFR were obtained
when CASMCs were treated with thrombin in the presence of EGFR antagonist, AG1478. For
Fig 1. Summary of RNA-sequencing data. Average mapping statistics for each of individual treatments using TopHat. RNA extraction from
human CASMCs A Untreated B treated with thrombin for 6 hours C treated with thrombin in the presence of AG1478 (5μM) D treated with
thrombin in the presence of SB431542 (10μM) E treated with thrombin in the presence of both AG1478 and SB431542.
https://doi.org/10.1371/journal.pone.0180842.g001
GPCR transactivation signalling
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this treatment, there was a total of 2 pooled samples (Fig 1C) with an average of 13.5 million
reads, 82.3% of these reads were mapped to the human reference genome (hg19). To determine
the number of differentially expressed genes occurring via the transactivation of the TGFBR1,
CASMCs were treated with thrombin in the presence of TGFBR1 antagonist, SB431542. For this
treatment group there was a total of 4 samples pooled together (Fig 1D) with an average read of
13.1 million reads. Among the total number of reads 81.2% of the reads were mapped to the
human reference genome (hg19). The treatment showing the genes regulated via dual transactiva-
tion dependent signalling pathways were treated with thrombin in the presence of EGFR and
TGFBR1 antagonists AG1478 and SB431542, respectively (Fig 1E). A total of 3 individual samples
were pooled to give an average of 10.9 million reads. Among the total reads 82.2% of the reads
were aligned to the human genome (hg19).
The small sample size in our RNA-Seq study is consistent with other RNA-Seq sequencing
studies published which are based on sample sizes of equal to or less than 3 [35]. In human
samples greater than 80% of the read pairs can be expected to be mapped to the reference
genome [47]. Consistent with the literature [48] the output from our RNA-Seq study shows
that over 80% of the reads are mapped to the human genome. This analysis validates that the
RNA used to identify the differentially expressed genes are of high quality.
GPCR mediated transactivation of PTKR and S/TKR accounts for over
half of GPCR mediated signalling
To assess the contribution of transactivation dependent signalling to overall GPCR signalling,
RNA sequencing was conducted. To study the role of PTKR, the EGFR antagonist, AG1478,
was used and to study S/TKR transactivation the TGFBR1 antagonist, SB431542, was utilized.
We have previously reported that at the concentrations used there is no cross over of inhibi-
tory activity from either drug to either of the target samples [49]. In the present study the dif-
ferential expression analysis was carried out using a multiple comparison software analysis,
edgeR. Each of the treated samples was initially compared to the basal sample. The samples
treated with thrombin in the presence of the receptor antagonists were further compared to
the CASMCs treated with thrombin alone. The results from this multiple comparison are pre-
sented in Fig 2.
Thrombin treatment of human CASMCs resulted in 293 differentially expressed genes
increasing in expression as compared to basal. A total of 209 genes were differentially regulated
when CASMCs were treated with thrombin in the presence of AG1478. In the presence of
AG1478, 80 of the 209 differentially expressed genes had an increase in expression as com-
pared to thrombin treatment alone. The remaining 129 genes differentially regulated by
AG1478 had a decrease in expression as compared to thrombin treatment alone (Fig 2). A
total of 177 genes are differentially expressed when CASMCs are treated with thrombin in the
presence of SB431542. The expression of 26 genes increase in the presence of SB431542 as
compared to thrombin treatment alone and 151 genes have a decrease in expression in the
presence of the antagonist as compared to thrombin treatment alone (Fig 2). When the two
antagonists were combined, a total of 212 genes were differentially expressed, the expression of
166 genes was decreased in the presence of dual antagonists as compared to thrombin and the
expression of 46 genes were increased as compared to thrombin treatment alone (Fig 2). Thus
these results show that transactivation dependent signalling plays an important role in GPCR
signalling with 209 genes regulated via the transactivation of the EGFR, 177 genes regulated
via thrombin transactivation of the TGFBR1 and 212 genes regulated via dual transactivation
of the EGFR and TGFBR1.
GPCR transactivation signalling
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Over the past two decades there have been studies expanding on GPCR mediated transacti-
vation signalling of PTKR specifically the EGFR [39, 50, 51]. GPCR mediated transactivation
dependent signalling also spans out to include activation of the TGFBR1. Although this latter
pathway was first identified a decade ago [17], there has been a limited amount of studies
investigating this transactivation pathway as compared to investigations into the transactiva-
tion of the EGFR. Interestingly, the results of this RNA sequencing data show that transactiva-
tion dependent signalling via the TGFBR1 is equally as important as transactivation of the
EGFR as there is a large number of genes regulated when CASMCs are treated with the respec-
tive receptor antagonists in the presence of thrombin.
Of the total number of genes differentially regulated by the individual treatments, a Venn
diagram was composed to show commonly regulated genes between the individual transactiva-
tion dependent pathways (Fig 3). Of the 209 genes differentially expressed by thrombin transac-
tivation of the EGFR, there were 14 genes common to transactivation of TGFBR1 and 19 genes
were found to be common in thrombin transactivation of the EGFR and in transactivation of
both EGFR and TGFBR1. The genes differentially expressed by thrombin transactivation of the
EGFR have 50 genes, which are not common with either of the other two treatments (Fig 3).
Fig 2. Number of genes regulated by thrombin transactivation of the EGFR and TGBR1 or both in vascular smooth muscle cells.
Thrombin compared to basal treatment has a total of 293 genes up regulated. Thrombin transactivation of the EGFR denoted by thrombin
in the presence of EGFR antagonist AG1478 has a total of 209 genes differentially regulated (80 up regulated and 129 down regulated).
Thrombin transactivation of TGFBR1 denoted by thrombin in the presence of TGFBR1 antagonist SB431542 has a total of 177 genes
differentially regulated (26 up regulated and 151 down regulated). Thrombin transactivation of both EGFR and TGFBR1 results in 212
genes differentially regulated (46 up regulated and 166 down regulated).
https://doi.org/10.1371/journal.pone.0180842.g002
GPCR transactivation signalling
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Thrombin transactivation of the TGFBR1 results in 177 differentially expressed genes, 20 of
these genes are in common with thrombin transactivation of both the EGFR and TGFBR1, and
17 genes are specific to transactivation of the TGFBR1. The three individual lists of differentially
expressed genes from each of the transactivation pathways share 126 genes which are common.
This shows that over 60% of the differentially expressed genes are common between the transac-
tivation dependent signalling pathways. These results indicate that although these two transacti-
vation dependent pathways are independent of each other and their biochemical pathways are
Fig 3. Depicted is the Venn diagram showing the differentially expressed genes of each of the
treatments. Thrombin transactivation of the EGFR (209 genes), thrombin transactivation of the TGFBR1
(177 genes) and thrombin transactivation of both EGFR and TGFBR1 (212 genes).
https://doi.org/10.1371/journal.pone.0180842.g003
GPCR transactivation signalling
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mechanistically distinct, they regulate over 60% of the same genes which may indicate that they
may be involved in regulating common biological processes.
There are a number of common downstream signalling intermediates which are common to
both EGFR and TGFBR1 signalling. MAPKs such as Erk, p38 and Jnk are amongst the common
signalling intermediates between the two pathways. MAPKs play a role in transmitting extracel-
lular signals from cell surface receptors to intracellular target and are activated by both TGF-β
[52–55] and EGF [56–58]. Similarly other serine/threonine kinases such as PI3K and glycogen
synthase kinase 3 are common downstream intermediates to both these signalling pathways [57,
59–63]. Thus common downstream signalling intermediates may allow for convergence; allow-
ing for over 60% of differentially expressed genes to be common between the two pathways.
The differential expression data was divided into the up and down regulated genes of each
of the transactivation pathways. The Venn diagram in Fig 4 illustrates that from the 80 genes
Fig 4. Depicted is the Venn diagram showing the genes up and down regulated by each of the
transactivation dependent signalling pathways. 209 genes are differentially expressed via thrombin
transactivation of the EGFR (80 upregulated and 129 down regulated) and 177 genes are differentially
expressed via thrombin transactivation of the TGFBR1 (26 upregulated and 141 down regulated).
https://doi.org/10.1371/journal.pone.0180842.g004
GPCR transactivation signalling
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up regulated in thrombin transactivation of EGFR, 19 genes are also commonly up regulated
in thrombin transactivation of the TGFBR1. There are 129 genes that are down regulated via
thrombin transactivation of the EGFR and of this gene list 108 are commonly down regulated
in thrombin mediated transactivation of the TGFBR1. Interestingly there are 13 genes which
are up regulated in thrombin transactivation of the EGFR and down regulated in transactiva-
tion of the TGFBR1 (Fig 4). These results show that over 80% of the genes down regulated by
either pathway are common with only 33% of EGFR mediated transactivation dependent sig-
nalling to be specific to EGFR and 20% of genes specific to TGFBR1 transactivation.
Genes most up and down regulated by the individual transactivation
dependent pathways
Overall, there were 209 genes differentially regulated by thrombin transactivation of the EGFR
(Fig 2). The top 10 up regulated genes are involved in molecular functions such as cytokine
activity which controls cell growth, survival and differentiation as well as genes which are
involved in transcription factor activity (Table 1). The top most down regulated genes via
EGFR transactivation are involved in receptor protein activity and protein kinase binding
(Table 1).
There were a total of 177 genes regulated by thrombin transactivation of the TGFBR1
(Table 2). The top 10 most upregulated genes include genes which were associated with GTP-
binding including TUBB2A, TUBB4B and TUBA1C (Table 2). Also included in the top most
up regulated genes by thrombin transactivation of the TGFBR1 were genes associated with
phospholipid binding and phosphatase activity. The majority of the genes down regulated by
Table 1. Genes most up regulated and down regulated by thrombin transactivation of the EGFR in vascular smooth muscle cells.
Most Up regulated
Gene ID Gene Gene Title Thr Thr+AG
ENSG00000123358 NR4A1 Nuclear receptor subfamily 4 group A member 1 14.02 19.63
ENSG00000100311 PDGFB Platelet-Derived Growth Factor Beta Polypeptide 6.74 7.05
ENSG00000109321 AREG Amphiregulin 6.87 6.92
ENSG00000115009 CCL20 Chemokine (C-C Motif) Ligand 20 4.67 6.42
ENSG00000197632 SERPINB2 Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 2 1.34 5.01
ENSG00000136244 IL6 Interleukin 6 3.82 4.63
ENSG00000154319 FAM167A Family With Sequence Similarity 167, Member A 3.08 4.38
ENSG00000120738 EGR1 Early Growth Response 1 1.39 4.30
ENSG00000117525 F3 Coagulation Factor III (Thromboplastin, Tissue Factor) 2.27 3.83
ENSG00000168389 MFSD2A Major Facilitator Superfamily Domain Containing 2A 1.41 3.59
Most down regulated
Gene ID Gene Gene Title Thr Thr+AG
ENSG00000127951 FGL2 Fibrinogen-Like 2 16.22 3.12
ENSG00000153234 NR4A2 Nuclear receptor subfamily 4 group A member 2 9.09 8.15
ENSG00000102760 RGCC Regulator Of Cell Cycle 8.99 4.09
ENSG00000119508 NR4A3 Nuclear receptor subfamily 4 group A member 3 8.11 4.92
ENSG00000095752 IL11 Interleukin 11 6.14 3.03
ENSG00000144063 MALL Mal, T-Cell Differentiation Protein-Like 5.81 1.16
ENSG00000162494 LRRC38 Leucine Rich Repeat Containing 38 5.48 3.87
ENSG00000078401 EDN1 Endothelin 1 5.17 1.02
ENSG00000111859 NEDD9 Neural Precursor Cell Expressed, Developmentally Down-Regulated 9 4.92 2.06
ENSG00000106278 PTPRZ1 Protein Tyrosine Phosphatase, Receptor-Type, Z Polypeptide 1 4.57 1.03
https://doi.org/10.1371/journal.pone.0180842.t001
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this transactivation dependent pathway include genes which were associated with transcrip-
tion factor activity (Table 2).
Treatment with the two receptor antagonists to assess the contribution of all the transac-
tivation dependent signalling showed 212 genes differentially expressed. The top 10 most
upregulated genes of this transactivation pathway were associated with transcription factor
activity, cytokine activity and receptor binding activity (Table 3). From the list of differen-
tially expressed genes occurring via the transactivation of both receptors the most down reg-
ulated genes are associated with receptor protein and cytokine activity.
Interestingly many of the top 10 up and down regulated genes are common between the
three treatments. Amongst the top 10 most up regulated genes in thrombin transactivation of
the EGFR (Table 1) and via dual transactivation dependent pathways are NR4A1, CCL20 and
IL6 (Table 3). These genes are involved in regulating transcription factor, cytokine and growth
factor activity. The SERPINB2 and the EGR1 are common in the top up regulated genes in
thrombin transactivation of EGFR (Table 1) and TGFBR1 (Table 2). Interestingly although
these two genes are in the top upregulated genes of each of the transactivation dependent path-
ways when the two receptor antagonists were used together these genes did not appear to be in
the top 10 most upregulated genes.
In the top most down regulated genes of each of the treatments there were more than 70%
commonly expressed genes. The top 10 most down regulated genes dependent on transactiva-
tion of the EGFR, TGFBR1 or both pathways have FGL2, PGCC, IL11, MALL, LRRc38 and
EDN1 common between the three conditions (Tables 1–3). These genes are commonly associ-
ated with cytokine activity and receptor binding. The NR4A2 and NR4A3 genes are common
Table 2. Genes most up regulated and down regulated by thrombin transactivation of the TGFBR1 in vascular smooth muscle cells.
Most Up regulated
Gene ID Gene Gene Title Thr Thr+SB
ENSG00000171246 NPTX1 Neuronal Pentraxin I 1.62 6.26
ENSG00000197632 SERPINB2 Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 2 1.34 4.68
ENSG00000120738 EGR1 Early Growth Response 1 1.39 4.55
ENSG00000168389 MFSD2A Major Facilitator Superfamily Domain Containing 2A 1.41 3.28
ENSG00000137267 TUBB2A Tubulin, Beta 2A Class Iia 2.38 3.16
ENSG00000138166 DUSP5 Dual Specificity Phosphatase 5 1.46 3.12
ENSG00000188229 TUBB4B Tubulin, Beta 4B Class Ivb 1.67 2.90
ENSG00000167553 TUBA1C Tubulin, Alpha 1c 1.99 2.85
ENSG00000173641 HSPB7 Heat Shock 27kDa Protein Family, Member 7 (Cardiovascular) 1.45 2.66
ENSG00000128228 SDF2L1 Stromal Cell-Derived Factor 2-Like 1 1.41 2.61
Most down regulated
Gene ID Gene Gene Title Thr Thr+SB
ENSG00000127951 FGL2 Fibrinogen-Like 2 16.26 4.43
ENSG00000123358 NR4A1 Nuclear receptor subfamily 4 group A member 1 14.07 10.21
ENSG00000153234 NR4A2 Nuclear receptor subfamily 4 group A member 2 9.11 3.93
ENSG00000102760 RGCC Regulator Of Cell Cycle 9.00 2.59
ENSG00000119508 NR4A3 Nuclear receptor subfamily 4 group A member 3 8.12 3.24
ENSG00000100311 PDGFB Platelet-Derived Growth Factor Beta Polypeptide 6.76 1.31
ENSG00000095752 IL11 Interleukin 11 6.16 0.84
ENSG00000144063 MALL Mal, T-Cell Differentiation Protein-Like 5.81 1.84
ENSG00000162494 LRRC38 Leucine Rich Repeat Containing 38 5.50 2.46
ENSG00000078401 EDN1 Endothelin 1 5.18 0.46
https://doi.org/10.1371/journal.pone.0180842.t002
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in the top 10 most down regulated genes in thrombin transactivation of TGFBR1 (Table 2)
and transactivation of the EGFR (Table 1), interestingly when the two receptor antagonists
were applied together (Table 3) these two genes are amongst the top most up regulated genes.
The NR4A1 gene found in the most up regulated genes in thrombin transactivation of the
EGFR (Table 1) and dual transactivation (Table 3) is amongst the top most down regulated
gene via thrombin transactivation of the TGFBR1 (Table 1). Similarly, the PDGFB and the
AREG genes associated with protein heterodimerization and EGFR binding, respectively were
found in the top 10 most down regulated genes in the dual transactivation dependent signal-
ling (Table 3) and in the top 10 most up regulated genes in thrombin transactivation of the
EGFR alone (Table 1). These results show that while genes may be up/down regulated when
the dual transactivation pathways are activated, the genes may act opposing in the presence of
a single receptor antagonist thus showing the complex nature of transactivation dependent
signalling.
In ovarian cancer cells the ET-1 receptor transactivates the EGFR [64, 65] and the vascular
endothelial growth factor receptor [66] leading to the expression of EDN1. The expression of
EDN1 has also been shown to be involved in colon and prostate cancer cell lines [67, 68].
EDN1 is one of the most down regulated genes in thrombin mediated transactivation of the
TGFBR1 (Table 2) and is highly down regulated in the presence of receptor antagonists to
both transactivation receptor pathways (Table 3). The role of EDN1 in GPCR mediated trans-
activation of S/TKR is unknown however EDN1 has a binding site for TGF-β activated Smad
transcription factor [69]. In palate development TGF-β treatment increased the expression of
EDN1 [70], thus consistent with our results which show that thrombin can transactivate the
Table 3. Genes most up regulated and down regulated by thrombin transactivation of the TGFBR1 and EGFR in vascular smooth muscle cells.
Most Up regulated
Gene ID Gene Gene Title Thr Thr+AG+SB
ENSG00000123358 NR4A1 Nuclear receptor subfamily 4 group A member 1 14.05 16.91
ENSG00000153234 NR4A2 Nuclear receptor subfamily 4 group A member 2 9.10 20.95
ENSG00000119508 NR4A3 Nuclear receptor subfamily 4 group A member 3 8.12 7.14
ENSG00000115009 CCL20 Chemokine (C-C Motif) Ligand 20 4.69 6.88
ENSG00000136244 IL6 Interleukin 6 3.83 4.50
ENSG00000073756 PTGS2 Prostaglandin-Endoperoxide Synthase 2 3.33 3.81
ENSG00000146374 RSPO3 R-Spondin 3 2.50 2.74
ENSG00000115008 IL1A Interleukin 1, Alpha 2.45 2.73
ENSG00000143878 RHOB Ras Homolog Family Member B 2.42 2.70
ENSG00000088826 SMOX Spermine Oxidase 2.14 2.21
Most down regulated
Gene ID Gene Gene Title Thr Thr+AG+SB
ENSG00000127951 FGL2 Fibrinogen-Like 2 16.26 4.14
ENSG00000102760 RGCC Regulator Of Cell Cycle 9.00 3.48
ENSG00000109321 AREG Amphiregulin 6.89 3.93
ENSG00000100311 PDGFB Platelet-Derived Growth Factor Beta Polypeptide 6.75 2.82
ENSG00000095752 IL11 Interleukin 11 6.16 1.51
ENSG00000144063 MALL Mal, T-Cell Differentiation Protein-Like 5.81 1.65
ENSG00000162494 LRRC38 Leucine Rich Repeat Containing 38 5.51 1.56
ENSG00000078401 EDN1 Endothelin 1 5.19 0.55
ENSG00000111859 NEDD9 Neural Precursor Cell Expressed, Developmentally Down-Regulated 9 4.93 1.61
ENSG00000106278 PTPRZ1 Protein Tyrosine Phosphatase, Receptor-Type, Z Polypeptide 1 4.59 1.23
https://doi.org/10.1371/journal.pone.0180842.t003
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TGFBR1 which is involved in the regulation of EDN1. Thus showing that thrombin transacti-
vation of the TGFBR1 and EGFR has the potential to be involved in growth related diseases
such as cancer and palate development.
Biological processes regulated by the transactivation dependent
pathways
In order to examine the biological processes influenced by each of the transactivation path-
ways, genes differentially expressed by the different treatments were subjected to functional
enrichment analysis based on their gene ontology (GO) annotations. From the 209 differen-
tially expressed and regulated genes by thrombin transactivation of the EGFR, there was 512
GO terms with a false discovery rate (FDR) value of less than 0.05. The top 50 biological terms
occurring via thrombin transactivation of the EGFR are listed in Table 4. There was a total of
177 genes differentially regulated by thrombin transactivation of the TGFBR1, from this gene
list 428 GO terms with an FDR value of less than 0.05. The top 50 biological terms from the
428 genes associated with thrombin transactivation of the TGFBR1 listed in Table 5. Treat-
ment with two receptor antagonists to account for all the transactivation dependent signalling
resulted in 212 differentially expressed genes. From this list of genes 440 terms were enriched
by dual transactivation dependent signalling. The top 50 GO terms respective to this signalling
cascade are listed in Table 6.
From the lists of the top 50 processes most significantly enriched by transactivation depen-
dent signalling, 28 terms were found to be common between the three lists (Tables 4–6). Many
of these GO terms are associated with regulation of cell activity as well as terms which are asso-
ciated with vascular development. This includes development of the cardiovascular system, cir-
culatory system, vasculature and blood vessel. From the list of 50 terms associated with dual
transactivation dependent signalling (Table 6), five enriched terms were common to thrombin
transactivation of the TGFBR1 (Table 5). The common terms include biological processes
which are involved in cell growth, cell death and tissue development. Similarly there were five
GO terms which were common to dual transactivation dependent signalling (Table 6) and
thrombin transactivation of the EGFR (Table 4). Terms common to these two lists include bio-
logical processes associated with the regulation of angiogenesis, vasculature development and
blood vessel morphogenesis as well as terms involved in cellular activity. When comparing the
terms regulated by transactivation of the TGFBR1 (Table 5) and the EGFR (Table 4) there are
5 GO terms which are common to these two pathways which were not found in the top 50 list
of terms via dual transactivation (Table 6). These 5 terms are associated with regulation of met-
abolic processes and signal transduction. Furthermore, network analysis was conducted using
String DB, Figs 5–7 show the networks over represented in the gene list of the respective trans-
activation dependent pathways.
The results above show that thrombin transactivation of the EGFR, TGFBR1 or both recep-
tors is involved in regulating a large number of biological processes 512, 428 and 440 terms,
respectively. With the two transactivation dependent pathways being mechanistically distinct
[15], the results of these experiments show that over 55% of the top 50 terms regulated are
common between the three treatments. Over 60% of the differentially expressed genes
described earlier were common to both thrombin mediated transactivation of the TGFBR1
and transactivation of the EGFR. The common differentially expressed genes resulted in over
55% biological terms, which are common between both transactivation pathways. The com-
monality between the two individual pathways is due the EGFR pathway sharing common
downstream signalling intermediates with the TGFBR1 downstream pathway. Serine/threo-
nine kinases such as MAPKs [52–55] are one of many common downstream intermediates to
GPCR transactivation signalling
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Table 4. The top 50 gene ontology terms in the analysis of genes expressed in thrombin transactivation of the EGFR.
GO ID GO Term Count FDR
GO.0051272 positive regulation of cellular component movement 24 3.87E-10
GO.0070887 cellular response to chemical stimulus 57 4.94E-10
GO.0071310 cellular response to organic substance 51 4.94E-10
GO.1901342 regulation of vasculature development 19 4.94E-10
GO.2000147 positive regulation of cell motility 23 4.94E-10
GO.0051094 positive regulation of developmental process 38 1.15E-09
GO.0030335 positive regulation of cell migration 22 1.51E-09
GO.0045765 regulation of angiogenesis 17 6.90E-09
GO.2000145 regulation of cell motility 28 7.31E-09
GO.0030334 regulation of cell migration 27 8.80E-09
GO.1904018 positive regulation of vasculature development 14 8.80E-09
GO.0009653 anatomical structure morphogenesis 51 1.09E-08
GO.0051270 regulation of cellular component movement 29 1.32E-08
GO.0051239 regulation of multicellular organismal process 54 1.85E-08
GO.0042981 regulation of apoptotic process 40 1.89E-08
GO.0043067 regulation of programmed cell death 40 2.16E-08
GO.0001568 blood vessel development 23 2.38E-08
GO.0050793 regulation of developmental process 50 2.41E-08
GO.0022603 regulation of anatomical structure morphogenesis 31 2.59E-08
GO.0042127 regulation of cell proliferation 41 2.59E-08
GO.0001944 vasculature development 23 5.07E-08
GO.0072358 cardiovascular system development 29 7.69E-08
GO.0072359 circulatory system development 29 7.69E-08
GO.0040012 regulation of locomotion 27 9.01E-08
GO.0051240 positive regulation of multicellular organismal process 38 9.01E-08
GO.0010033 response to organic substance 53 1.83E-07
GO.0048514 blood vessel morphogenesis 20 1.88E-07
GO.0051726 regulation of cell cycle 31 1.93E-07
GO.0042221 response to chemical 68 2.21E-07
GO.0048468 cell development 41 2.60E-07
GO.0045766 positive regulation of angiogenesis 12 2.79E-07
GO.0048583 regulation of response to stimulus 63 2.79E-07
GO.0014070 response to organic cyclic compound 28 2.83E-07
GO.0008284 positive regulation of cell proliferation 28 2.92E-07
GO.0071407 cellular response to organic cyclic compound 19 3.23E-07
GO.0071840 cellular component organization or biogenesis 79 5.43E-07
GO.0010941 regulation of cell death 38 7.50E-07
GO.0032879 regulation of localization 49 7.79E-07
GO.0001525 angiogenesis 17 1.04E-06
GO.0051128 regulation of cellular component organization 47 1.04E-06
GO.0009966 regulation of signal transduction 50 1.23E-06
GO.0006928 movement of cell or subcellular component 35 1.73E-06
GO.2000026 regulation of multicellular organismal development 38 1.86E-06
GO.0043065 positive regulation of apoptotic process 22 2.16E-06
GO.0065009 regulation of molecular function 53 2.16E-06
GO.0071495 cellular response to endogenous stimulus 30 2.37E-06
GO.0019220 regulation of phosphate metabolic process 37 3.60E-06
(Continued )
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both the transactivation dependent pathways and may play a role in the convergence of the
two signalling pathways to regulate the same biological processes.
Our lab has focused on GAG elongation because of its association with atherosclerosis but
also because signalling pathways for GAG elongation are distinct from their signalling com-
mon responses such as protein signalling and cell proliferation [14–16, 71]. Never the less
GAG elongation has also been an excellent response to characterise transactivation dependent
signalling and in that context our work has shown how transactivation dependent signalling
makes a major contribution to PAR-1 signalling.
Transactivation dependent signalling is associated with genes regulating
vasculature development
To assess the processes influenced by transactivation dependent signalling, the differentially
expressed genes were subjected to functional enrichment analysis based on their GO annota-
tions. The biological processes most commonly enriched by the three treatments were linked
with vascular development (GO.0072358 Table 7). There were 29 genes associated with cardio-
vascular system development in thrombin transactivation of the EGFR (Table 4); 28 genes in
thrombin transactivation of the TGFBR1 (Table 5) and 31 genes in thrombin transactivation
of both the TGFBR1 and EGFR (Table 6). All the genes were up regulated by thrombin when
compared to basal and down regulated in the presence of AG1478 with the exception of EGR1,
HES1, NR4A1, PDGFB, RHOB, SPHK1 and TIPARP (Table 7). In the presence of thrombin
and TGFBR1 antagonist, SB431542, most of the genes associated with cardiovascular system
development were down regulated with the exception of EGR1 and TIPARP (Table 7). When
looking at dual transactivation dependent signalling associated with cardiovascular system
development all genes apart from EGR1, HES1 ID1, KLFS, NR4A1, PTGS2 and RHOB were
down regulated as compared to thrombin stimulation alone (Table 7).
The EGR1 (early growth response 1) gene associated with cardiovascular system develop-
ment was regulated by the three treatments when compared to thrombin (Table 7). EGR1 is
involved in the development of atherosclerotic lesions and has been shown to play a role in
regulating neointimal thickening in response to vascular injury [72–75]. Thrombin mediated
GAG chain elongation evaluated by the mRNA expression of CHST11 and CHSY1 was inhib-
ited in the presence of antagonists to the EGFR and TGFBR1 [33]. However the RNA-Sequen-
cing results show that with treatment of the receptor antagonists in the presence of the
thrombin there is an increase in the expression of the EGR1 gene, this may be due to earlier
work looking at the pre-inflammatory phase of atherosclerosis. The EGR1 gene is commonly
involved in the neointimal thickening which is in the inflammatory phase of atherogenesis.
The ANKRD1 (Ankyrin Repeat Domain 1) gene belongs to the conserved muscle Ankyrin
repeat family and is induced in response to inflammation, injury and response to cell stress
[76, 77]. The ANKRD1 gene is amongst the differentially expressed genes associated with vas-
cular development. The ANKRD1 gene was involved in the transactivation of the EGFR and
the TGFBR1 (Table 7). ANKRD1 is directly mediated via TGF-β mediated signalling as the
ANKRD1 promotor region contains a Smad binding motif [78, 79]. The ANKRD1 gene is
Table 4. (Continued)
GO ID GO Term Count FDR
GO.0009605 response to external stimulus 42 3.92E-06
GO.0048519 negative regulation of biological process 70 4.03E-06
GO.1902531 regulation of intracellular signal transduction 35 4.43E-06
https://doi.org/10.1371/journal.pone.0180842.t004
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Table 5. The top 50 gene ontology terms in the analysis of genes expressed in thrombin transactivation of the TGFBR1.
GO ID GO Term Count FDR
GO.0051094 positive regulation of developmental process 34 1.63E-08
GO.0009653 anatomical structure morphogenesis 46 1.66E-08
GO.0030334 regulation of cell migration 25 1.66E-08
GO.0070887 cellular response to chemical stimulus 48 1.66E-08
GO.0071310 cellular response to organic substance 43 1.66E-08
GO.0072358 cardiovascular system development 28 1.66E-08
GO.0072359 circulatory system development 28 1.66E-08
GO.0019220 regulation of phosphate metabolic process 37 8.63E-08
GO.0031399 regulation of protein modification process 38 8.63E-08
GO.0051239 regulation of multicellular organismal process 47 9.10E-08
GO.0048468 cell development 38 1.03E-07
GO.1902531 regulation of intracellular signal transduction 35 1.04E-07
GO.0030335 positive regulation of cell migration 18 1.35E-07
GO.0051270 regulation of cellular component movement 25 1.42E-07
GO.0048519 negative regulation of biological process 65 2.26E-07
GO.0042981 regulation of apoptotic process 34 2.67E-07
GO.0040012 regulation of locomotion 24 2.81E-07
GO.0043067 regulation of programmed cell death 34 2.81E-07
GO.0009888 tissue development 36 3.06E-07
GO.0030154 cell differentiation 53 4.72E-07
GO.0051240 positive regulation of multicellular organismal process 33 4.72E-07
GO.0050793 regulation of developmental process 42 4.79E-07
GO.1901342 regulation of vasculature development 14 5.83E-07
GO.0007507 heart development 19 7.20E-07
GO.0045597 positive regulation of cell differentiation 25 7.20E-07
GO.0009966 regulation of signal transduction 45 7.39E-07
GO.0009892 negative regulation of metabolic process 46 8.03E-07
GO.0065009 regulation of molecular function 48 8.03E-07
GO.0042221 response to chemical 58 1.34E-06
GO.0042325 regulation of phosphorylation 31 1.34E-06
GO.0048583 regulation of response to stimulus 54 1.34E-06
GO.0010033 response to organic substance 45 1.48E-06
GO.0044057 regulation of system process 18 1.60E-06
GO.0051128 regulation of cellular component organization 41 2.63E-06
GO.0051726 regulation of cell cycle 26 3.13E-06
GO.0016477 cell migration 23 3.49E-06
GO.0001932 regulation of protein phosphorylation 29 3.61E-06
GO.0045937 positive regulation of phosphate metabolic process 26 3.67E-06
GO.0001568 blood vessel development 18 3.71E-06
GO.0048869 cellular developmental process 52 4.09E-06
GO.0050790 regulation of catalytic activity 41 4.57E-06
GO.0071407 cellular response to organic cyclic compound 16 4.58E-06
GO.2000026 regulation of multicellular organismal development 33 5.80E-06
GO.0048523 negative regulation of cellular process 58 5.83E-06
GO.0051246 regulation of protein metabolic process 43 6.58E-06
GO.0001944 vasculature development 18 6.70E-06
GO.0042127 regulation of cell proliferation 32 7.24E-06
(Continued )
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associated with the actin cytoskeleton signalling network [80], in our model thrombin medi-
ated transactivation of the TGFBR1 activates Rho/ROCK signalling via cytoskeletal rearrange-
ment leading to the activation of cell surface integrins [15]. Thus demonstrating a potential
signalling pathway for the activation of the ANKRD1 gene via thrombin transactivation of the
TGFBR1. The role of ANKRD1 downstream of the EGFR in unknown, however ANKRD1 is
induced by stress activated kinases [81–83] hence we speculate that thrombin mediated trans-
activation of the EGFR induces the expression of ANKRD1 via the activation of downstream
stress activated MAPKs (Erk, p38 and Jnk). MAPK mediated Smad2 linker region phosphory-
lation correlates with proteoglycan synthesis and GAG chain elongation [84, 85]. In VSMCs
thrombin mediated transactivation of the EGFR and TGFBR1 result in the phosphorylation of
transcription factor Smad2 in the linker region. Thus GPCR mediated expression of ANKRD1
may signal via Smad2 linker region dependent pathways.
To validate the data from the RNA-Seq experiments we investigated thrombin mediated
mRNA and protein expression of ANKRD1. Thrombin treated CASMCs lead to a 1.5-fold
increase in ANKRD1 mRNA expression (Fig 8A). In the presence of TGFBR1 antagonist,
SB431542 and EGFR antagonist, AG1478 individually and together they completely abolished
thrombin mediated mRNA expression of ANKRD1 (Fig 8A). The protein expression follows a
similar pattern, treatment with thrombin increased ANKDR1 protein levels to 1.5-fold (Fig
8B) in the presence of the two receptor antagonists thrombin mediated ANKDR1 protein
expression is completely inhibited. Thus these results validate the genes that were modulated
in this RNA-Seq screen.
Conclusions
GPCRs are one of the most successful class of drug targets on the human genome for the treat-
ment of a variety of diseases [86, 87]. Hence the role of GPCR signalling is of great interest to
medical research. GPCRs signal in three main mechanisms, which includes signalling via G
proteins to secondary messenger intermediates and via utilization of the signalling pathway
and via the utilization of a β-arrestin molecule both which have been extensively reviewed [19,
88]. The third GPCR signalling pathway is via transactivation of PTKR and via transactivation
of S/TKR. We subsequently described S/TKR transactivation but again the contribution to
overall GPCR signalling was unknown. Hence in this present study, the aim was to determine
the contribution of dual transactivation of GPCR mediated signalling by utilizing RNA
sequencing to facilitate the identification of the genes regulated by these two transactivation
pathways. Using this approach, we have uncovered that thrombin mediated signalling results
in 293 differentially expressed genes of these genes approximately 50% of the signalling is
occurring via transactivation dependent signalling. Using this approach we have also uncov-
ered that transactivation of the TGFBR1 is as equally important as the transactivation of the
EGFR noting that the TGFBR1 transactivation pathway has not yet been as extensively
researched.
Hannan et al. [39] used a siRNA approach studied 720 kinase genes associated with Angio-
tensin II transactivation of the EGFR. Knockdown of 3 genes, TRIO, BMX and CHKA
Table 5. (Continued)
GO ID GO Term Count FDR
GO.0010941 regulation of cell death 32 7.49E-06
GO.0014070 response to organic cyclic compound 23 7.63E-06
GO.0006928 movement of cell or subcellular component 30 8.32E-06
https://doi.org/10.1371/journal.pone.0180842.t005
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Table 6. The top 50 gene ontology terms in the analysis of genes expressed in thrombin transactivation of both the EGFR and TGFBR1.
GO ID GO Term Count FDR
GO.0070887 cellular response to chemical stimulus 63 1.11E-12
GO.0071310 cellular response to organic substance 56 1.11E-12
GO.0051094 positive regulation of developmental process 39 9.25E-10
GO.0010033 response to organic substance 58 4.30E-09
GO.0030334 regulation of cell migration 28 4.30E-09
GO.0042221 response to chemical 74 4.30E-09
GO.0048468 cell development 45 1.04E-08
GO.0072358 cardiovascular system development 31 1.08E-08
GO.0072359 circulatory system development 31 1.08E-08
GO.0051240 positive regulation of multicellular organismal process 40 2.15E-08
GO.0042981 regulation of apoptotic process 40 4.01E-08
GO.0051239 regulation of multicellular organismal process 54 4.01E-08
GO.0043067 regulation of programmed cell death 40 4.27E-08
GO.0050793 regulation of developmental process 50 5.47E-08
GO.0030335 positive regulation of cell migration 20 6.37E-08
GO.0051270 regulation of cellular component movement 28 8.18E-08
GO.0071407 cellular response to organic cyclic compound 20 1.08E-07
GO.0071495 cellular response to endogenous stimulus 33 1.14E-07
GO.1901342 regulation of vasculature development 16 1.21E-07
GO.0009653 anatomical structure morphogenesis 49 1.22E-07
GO.0014070 response to organic cyclic compound 29 1.22E-07
GO.0040012 regulation of locomotion 27 1.27E-07
GO.0001568 blood vessel development 22 1.37E-07
GO.0051726 regulation of cell cycle 31 2.93E-07
GO.0048519 negative regulation of biological process 74 3.54E-07
GO.0010941 regulation of cell death 39 4.20E-07
GO.0045597 positive regulation of cell differentiation 28 5.27E-07
GO.0048522 positive regulation of cellular process 74 1.00E-06
GO.0048518 positive regulation of biological process 81 1.01E-06
GO.0042127 regulation of cell proliferation 38 1.22E-06
GO.0051716 cellular response to stimulus 90 1.38E-06
GO.0001944 vasculature development 21 1.41E-06
GO.0060548 negative regulation of cell death 29 1.41E-06
GO.0051241 negative regulation of multicellular organismal process 30 1.45E-06
GO.1901698 response to nitrogen compound 28 1.95E-06
GO.0045765 regulation of angiogenesis 14 1.97E-06
GO.0009892 negative regulation of metabolic process 51 2.92E-06
GO.0048583 regulation of response to stimulus 61 3.06E-06
GO.0032879 regulation of localization 48 3.55E-06
GO.0009888 tissue development 38 3.89E-06
GO.0009890 negative regulation of biosynthetic process 36 4.25E-06
GO.0033993 response to lipid 26 4.25E-06
GO.0043069 negative regulation of programmed cell death 27 4.39E-06
GO.0051128 regulation of cellular component organization 46 4.39E-06
GO.0010629 negative regulation of gene expression 36 4.58E-06
GO.0044057 regulation of system process 19 4.88E-06
GO.0048514 blood vessel morphogenesis 18 5.31E-06
GO.0022603 regulation of anatomical structure morphogenesis 27 5.70E-06
GO.1904018 positive regulation of vasculature development 11 5.71E-06
GO.0010632 regulation of epithelial cell migration 12 5.80E-06
https://doi.org/10.1371/journal.pone.0180842.t006
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revealed that their activity is required for Angiotensin II mediated transactivation of the EGFR
in human mammary epithelial cells [39]. This RNA-Seq sequencing study we explored all the
Fig 5. This network represents the differentially expressed genes regulated in thrombin transactivation of the EGFR. The functions of this network
include biological processes, molecular functions and cellular component. The color of the nodes indicates the query protein and its first shell of interactions.
Protein nodes which are enlarged indicates the availability of 3D protein structure information. The colored lines between the nodes indicated the query
protein-protein interactions. The known interactions is a light blue (from curated database) or pink (experimentally determined) lines between the proteins.
The predicted interactions use green (gene neighborhood), red (gene fusion) and dark blue (gene co-occurrence) lines. The yellow represents text mining,
the black represent co-expression and the purple lines represent protein homology.
https://doi.org/10.1371/journal.pone.0180842.g005
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genes that were involved in GPCR mediated transactivation of the EGFR and TGFBR1 in
human VSMCs. Although the two transactivation signalling pathways have been reported as
to be mechanistically distinct [14, 15] this study shows that these two pathways share in over
65% of the differentially expressed genes. The transactivation dependent signalling pathways
shared in over 55% of its top 50 enriched terms, with a majority of these GO terms associated
with cardiovascular system development.
The two transactivation dependent signalling pathways share in over 65% of common dif-
ferentially expressed genes. The most regulated genes of these transactivation mediated
Fig 6. This network represents the differentially expressed genes regulated in thrombin transactivation of the TGFBR1. The functions of this
network include biological processes, molecular functions and cellular component. The color of the nodes indicates the query protein and its first shell of
interactions. Protein nodes which are enlarged indicates the availability of 3D protein structure information. The colored lines between the nodes indicated
the query protein-protein interactions. The known interactions is a light blue (from curated database) or pink (experimentally determined) lines between the
proteins. The predicted interactions use green (gene neighborhood), red (gene fusion) and dark blue (gene co-occurrence) lines. The yellow represents text
mining, the black represent co-expression and the purple lines represent protein homology.
https://doi.org/10.1371/journal.pone.0180842.g006
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pathways are involved in molecular functions such as cytokine activity which controls cell
growth survival and differentiation. Cytokine activity is involved in different aspects of cancer,
development, treatment and prognosis [89–91]. The EGFR [92–94] and the TGFBR1 [95–97]
signalling pathways alone play a role in cancer development. Both the EGFR and TGFBR1 sig-
nalling pathways share a common transcription factor, Smad2 linker region. The Smad2 linker
region plays a role in cancer development [98–100]. The Smad2 linker region is also associated
with other pathophysiological conditions which include but are not limited to proteoglycan
Fig 7. This network represents the differentially expressed genes regulated in thrombin transactivation of both the EGFR and TGFBR1. The
functions of this network include biological processes, molecular functions and cellular component. The color of the nodes indicates the query protein and its
first shell of interactions. Protein nodes which are enlarged indicates the availability of 3D protein structure information. The colored lines between the nodes
indicated the query protein-protein interactions. The known interactions is a light blue (from curated database) or pink (experimentally determined) lines
between the proteins. The predicted interactions use green (gene neighborhood), red (gene fusion) and dark blue (gene co-occurrence) lines. The yellow
represents text mining, the black represent co-expression and the purple lines represent protein homology.
https://doi.org/10.1371/journal.pone.0180842.g007
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synthesis and GAG chain elongation associated with atherosclerosis development [84, 85].
Thus showing that the linker region of the Smad2 may be a transcription factor of interest for
to study different biological process occurring via thrombin mediated transactivation of both
the EGFR and TGFBR1.
In summary, by generating and utilizing high throughput RNA-Seq data, we have identified
that GPCR signalling via transactivation of either of the EGFR or TGFBR1 account for 50% of
GPCR signalling. We have identified that these two pathways share in regulation of over 65%
of genes of which a majority are involved in the development of the vasculature. This work
provides the platform for investigating the molecular basis for transactivation dependent sig-
nalling and provides proof that genome wide studies can offer powerful insights into this
process.
Table 7. List of genes and respective fold change of expression associated with gene ontology term cardiovascular development. The differentially
expressed genes with no fold change presented in the table did not reach the statistical significance cut off (P<0.01 and Log2FC>0.7)
Gene ID Gene Name Thr Thr+AG Thr+SB Thr+SB+AG
ENSG00000148677 ANKRD1 3.514 0.612 0.962 0.352
ENSG00000183337 BCOR 1.646 0.533 0.543
ENSG00000118523 CTGF 2.662 1.251 0.901 0.933
ENSG00000142871 CYR61 2.631 2.133 2.298 2.024
ENSG00000164741 DLC1 1.755 0.731 0.901
ENSG00000078401 EDN1 5.188 1.013 0.458 0.547
ENSG00000120738 EGR1 1.394 4.249 4.505 3.684
ENSG00000196159 FAT4 1.292 0.601
ENSG00000176692 FOXC2 1.671 0.694
ENSG00000170961 HAS2 2.047 0.544 0.293
ENSG00000114315 HES1 3.058 3.152 1.154 3.115
ENSG00000100644 HIF1A 1.471 0.639 0.627
ENSG00000125968 ID1 4.482 0.626 0.775 0.194
ENSG00000115738 ID2 1.302 0.544 0.337
ENSG00000117318 ID3 3.315 1.153 0.814 0.549
ENSG00000121361 KCNJ8 2.129 0.706 0.894 0.637
ENSG00000102554 KLF5 2.679 1.933 2.141 2.690
ENSG00000085276 MECOM 1.673 0.437 0.488 0.486
ENSG00000164134 NAA15 1.639 0.793 0.804
ENSG00000162614 NEXN 1.815 0.821 0.876 0.886
ENSG00000086991 NOX4 2.015 0.566 0.347 0.423
ENSG00000123358 NR4A1 14.061 19.477 10.102 16.838
ENSG00000180914 OXTR 2.303 0.854 0.616 0.746
ENSG00000138650 PCDH10 1.322 0.667 0.613 0.581
ENSG00000100311 PDGFB 6.773 6.991 1.294 2.835
ENSG00000073756 PTGS2 3.350 3.195 2.066 3.791
ENSG00000127329 PTPRB 1.731 0.829
ENSG00000143878 RHOB 2.416 2.434 1.028 2.691
ENSG00000124216 SNAI1 1.783 0.650 1.174
ENSG00000176170 SPHK1 2.078 2.630 1.731 1.424
ENSG00000120156 TEK 1.936 0.543 0.549 0.576
ENSG00000163659 TIPARP 1.416 2.162 2.084
ENSG00000006327 TNFRSF12A 1.578 1.309
https://doi.org/10.1371/journal.pone.0180842.t007
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